The relationship between serum bilirubin and Crohn's disease

Inflammatory Bowel Diseases

Volumn 20, Issue 3, 2014, Pages 481-487

  Leníček, Martin ^a   Ďuricová, Dana ^b   Hradsky, Ondrej ^a   Dušátková, Petra ^a   Jirásková, Alena ^a   Lukáš, Milan ^a,b   Nachtigal, Petr ^a   Vítek, Libor ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b ISCARE Lighthouse   (Czech Republic)

Author keywords

Bilirubin; Bilirubin UDP glucuronosyl transferase; Crohn's disease; Gilbert's syndrome; Oxidative stress

Indexed keywords

BILIRUBIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; DINUCLEOTIDE; GLUCURONOSYLTRANSFERASE 1A1; HEME OXYGENASE 1;

ADOLESCENT; ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOCHEMISTRY; CASE CONTROL STUDY; CHILD; CLINICAL STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; EXPLORATORY RESEARCH; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GILBERT DISEASE; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; WILD TYPE;

ADOLESCENT; ADULT; BILIRUBIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GLUCURONOSYLTRANSFERASE; HEME OXYGENASE-1; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 84898762294     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000440817.84251.98     Document Type: Article

References (34)

1. D'Odorico A, Bortolan S, Cardin R, et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol. 2001;36:1289-1294.
2. Buffinton GD, Doe WF. Depleted mucosal antioxidant defences in inflammatory bowel disease. Free Rad Biol Med. 1995;19:911-918.
3. McKenzie SJ, Baker MS, Buffinton GD, et al. Evidence of oxidantinduced injury to epithelial cells during inflammatory bowel disease. J Clin Invest. 1996;98:136-141.
4. Kruidenier L, Kuiper I, Van Duijn W, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol. 2003; 201:17-27.
5. Levy E, Rizwan Y, Thibault L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000;71:807-815.
6. Wendland BE, Aghdassi E, Tam C, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr. 2001;74: 259-264.
7. Koutroubakis IE, Malliaraki N, Dimoulios PD, et al. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004;49:1433-1437.
8. Maor I, Rainis T, Lanir A, et al. Oxidative stress, inflammation and neutrophil superoxide release in patients with Crohn's disease: distinction between active and non-active disease. Dig Dis Sci. 2008;53:2208-2214.
9. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci U S A. 1988;85:9748-9752.
10. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem. 2007;43:1-57.
11. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006;86:583-650.
12. Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem. 2010;56:1535-1543.
13. Exner M, Minar E, Wagner O, et al. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Rad Biol Med. 2004;37:1097-1104.
14. Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1&z.ast;28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008;198:1-11.
15. Hausmann M, Paul G, Kellermeier S, et al. (GT)N dinucleotide repeat polymorphism of haem oxygenase-1 promotor region is not associated with inflammatory bowel disease risk or disease course. Clin Exp Immunol. 2008;153:81-85.
16. Paul G, Bataille F, Obermeier F, et al. Analysis of intestinal haemoxygenase-1 (HO-1) in clinical and experimental colitis. Clin Exp Immunol. 2005;140:547-555.
17. Wang WP, Guo X, Koo MWL, et al. Protective role of heme oxygenase-1 on trinitrobenzene sulfonic acid-induced colitis in rats. Am J Physiol Gastroint Liver Physiol. 2001;281:G586-G594.
18. Vitek L, Ostrow JD. Bilirubin chemistry and metabolism; harmful and protective aspects. Curr Pharm Des. 2009;15:2869-2883.
19. de Vries HS, te Morsche RH, Jenniskens K, et al. A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn's disease. J Crohns Colitis. 2012;6:597-602.
20. Hradsky O, Lenicek M, Dusatkova P, et al. Variants of CARD15, TNFA and PTPN22 and susceptibility to Crohn's disease in the Czech population: high frequency of the CARD15 1007fs. Tissue Antigens. 2008;71:538-547.
21. Jiraskova A, Lenicek M, Vitek L. Simultaneous genotyping of microsatellite variations in HMOX1 and UGT1A1 genes using multicolored capillary electrophoresis. Clin Biochem. 2010;43:697-699.
22. Andersen V, Ernst A, Christensen J, et al. The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med Genet. 2010;11:82.
23. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171-1175.
24. Kalousova M, Novotny L, Zima T, et al. Decreased levels of advanced glycation end-products in patients with Gilbert syndrome. Cell Mol Biol. 2005;51:387-392.
25. Krzystek-Korpacka M, Neubauer K, Berdowska I, et al. Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis. 2008;14:794-802.
26. Vitek L, Malikova I, Kvasnicka J, et al. Relationship between serum bilirubin and markers of inflammation and oxidative stress. J Gastroenterol Hepatol. 2007;22:A235.
27. Lanone S, Bloc S, Foresti R, et al. Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats. FASEB J. 2005;19:1890-1892.
28. Szanto I, Rubbia-Brandt L, Kiss P, et al. Expression of NOX1, a superoxidegenerating NADPH oxidase, in colon cancer and inflammatory bowel disease. J Pathol. 2005;207:164-176.
29. Hausmann M, Spottl T, Andus T, et al. Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages. Clin Exp Immunol. 2001;125:48-55.
30. Boschetti G, Nancey S, Sardi F, et al. Therapy with anti-TNFalpha antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17:160-170.
31. Phelan D, Winter GM, Rogers WJ, et al. Activation of the Ah receptor signal transduction pathway by bilirubin and biliverdin. Arch Biochem Biophys. 1998;357:155-163.
32. Stevens EA, Bradfield CA. Immunology: T cells hang in the balance. Nature. 2008;453:46-47.
33. Rocuts F, Zhang X, Yan J, et al. Bilirubin promotes de novo generation of T regulatory cells. Cell Transplant. 2010;19:443-451.
34. Ioannidis O, Varnalidis I, Paraskevas G, et al. Nutritional modulation of the inflammatory bowel response. Digestion. 2011;84:89-101.